‘I lost so much weight, my husband thought I was terminally ill’: why do people lie about taking Ozempic?

The dramatic results of weight-loss drugs often come with a side order of stigma, as though it’s ‘cheating’ not to stick to willpower, diet and exercise alone. Is that why so many are telling no one – not even their partners?

Health insurer Vitality is first to offer UK members weight-loss jabs

Company will give up to 20% off treatments such as Wegovy and Mounjaro through private cover

Soft spaces out, stick-fighting in: Dutch call for the return of risky play

Encouraging kids to play with fire? Hear us out, says party worried by the Netherlands’ increasingly sedentary ways

‘Wild west’: experts concerned by illegal promotion of weight-loss jabs in UK

Guardian review finds many online pharmacies flouting strict advertising rules that govern prescription-only drugs

Time for a noodle tax? Doctor who sounded alarm on ultra-processed food urges tougher action

Carlos Monteiro says the links between UPF and obesity, diabetes and even mental ill health are so strong that manufacturers should face taxes just like tobacco firms

Ozempic or Wegovy can be a godsend, but their non-medical use is alarming

Semaglutides are powerful drugs that carry risks, not tools for rapid weight loss, says professor of public health Devi Sridhar

Mounjaro is second obesity drug to be approved for use in England

Those with BMI of 35 and a comorbidity could be prescribed tirzepatide and Nice says it is more effective than Wegovy

Cash incentives may help men lose weight, research finds

Men with obesity offered incentives and sent healthy-eating tips in Game of Stones trial found to have lost most weight

Supermarkets in England ‘blatantly disregarding’ rules over where they place crisps, sweets and fizzy drinks

Survey found stores put foods high in fat, salt or sugar in prominent locations despite government regulations

Wegovy could mean the end of obesity? That’s bad news for politicians

It has been easy to scapegoat overweight people for Britain’s collapsing health system. No wonder this new drug is being launched so cautiously, writes Zoe Williams